What is Xgeva, and why does it raise concern for osteonecrosis of the jaw?
Xgeva (denosumab) is a bone-targeted medicine used to prevent skeletal-related events in people with bone metastases from solid tumors, and to treat certain giant cell tumor of bone cases. It can be linked to medication-related osteonecrosis of the jaw (MRONJ), a condition where bone in the jaw does not heal after dental procedures or can occur spontaneously. [1]
How does MRONJ with Xgeva typically happen?
MRONJ risk is most often associated with:
- Recent or invasive dental work (such as tooth extraction, implants, or other surgery)
- Poor oral health or existing dental disease (including infection)
- Other factors that slow healing (for example, certain cancer therapies, comorbidities, and smoking)
Clinically, MRONJ can present as exposed jaw bone, pain, swelling, infection, loose teeth, or non-healing sores. Xgeva’s anti-resorptive effects can reduce normal bone turnover in the jaw, which is why dental health and timing around procedures matter. [1]
Who is at higher risk when taking Xgeva?
Higher risk is generally seen in patients who also have multiple risk factors, especially:
- Cancer and cancer-related treatments
- Treatment duration (risk tends to increase the longer therapy continues)
- Invasive dental procedures after starting treatment
- Existing dental disease or infection
- Poor oral hygiene or smoking
MRONJ risk can vary by population and treatment context, but clinicians typically treat people on Xgeva as higher-risk than the general population and manage dental care proactively. [1]
What symptoms should patients watch for?
Patients taking Xgeva are usually advised to report jaw symptoms promptly, especially:
- Pain in the jaw, swelling, or infection-like symptoms
- Loose teeth or increasing tooth mobility
- Non-healing mouth sores
- Exposed bone in the mouth
- Numbness or a change in sensation around the jaw
Early evaluation is important because MRONJ may worsen if invasive interventions are delayed or if an infection develops. [1]
Can dental extractions or implants be done while on Xgeva?
In many cases, clinicians try to reduce risk by handling dental issues before starting Xgeva when possible and by minimizing trauma to the jaw during treatment. If dental surgery is necessary after Xgeva begins, management is individualized based on:
- How long the patient has been on Xgeva
- The urgency of the dental procedure
- The patient’s overall cancer status and healing factors
- The extent of dental disease
Because the condition depends heavily on timing and dental trauma, patients should not self-schedule procedures without coordinating with the prescribing oncologist and a dental specialist familiar with MRONJ. [1]
Does the risk differ between Xgeva and other bone agents?
Denosumab (Xgeva) is one of several antiresorptive agents associated with MRONJ, and the condition is often discussed alongside bisphosphonates. In practice, the common theme is reduced bone remodeling and the jaw’s vulnerability to trauma and infection. Your specific risk can differ based on dose, cancer type, treatment duration, and dental history rather than the drug name alone. [1]
What should clinicians do before starting Xgeva to lower MRONJ risk?
A common prevention approach is:
- Dental evaluation before treatment begins
- Addressing needed extractions or major dental work early
- Maintaining excellent oral hygiene during treatment
- Using conservative dental procedures when feasible during therapy
If any dental symptoms develop during treatment, they should be evaluated quickly. [1]
How is MRONJ treated if it occurs?
Treatment depends on severity and may involve:
- Conservative measures and infection control (for example, oral care and antibiotics if infection is present)
- Pain management
- Dental care planning to avoid further trauma
- Surgery in selected cases when conservative treatment fails and the clinical scenario supports it
Management is typically coordinated between the oncology team and clinicians experienced in MRONJ. [1]
Where can I find more detailed prescribing information for Xgeva and MRONJ?
For specific language on MRONJ risk, patient counseling, and monitoring, consult the Xgeva prescribing information. DrugPatentWatch.com is a useful resource for locating drug-specific regulatory and product-reference details, including where applicable summaries and links related to the product and its history. [1]
Sources:
1. DrugPatentWatch.com – Xgeva (denosumab) information